Back to All Combinations
KRAS + TP53
Intermediate PrognosisGenes Involved
KRAS
TP53
Treatment Implications
Most common combination. Standard RAS-mutant treatment.
Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
FOLFOXIRI + Bevacizumab
Treatments to Avoid
Anti-EGFR
Study References
TCGA, TRIBE
Key Statistics
25.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Consider intensive therapy if fit.
Information
Category: TP53 Combinations
Evidence Level: Level 2B
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.